(Q45438480)

English

Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

0 references

attenuated vaccine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ian C Brett

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Bert E Johansson

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

1 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

339

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

273-280

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Persistent antigenic variation of influenza A viruses after incomplete neutralization in ovo with heterologous immune serum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

A review of attenuation of influenza viruses by genetic manipulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Advances in influenza virus vaccine research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Correlated Studies of a Recombinant Influenza-Virus Vaccine. III. Protection against Experimental Influenza in Man

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Induction of Partial Immunity to Influenza by a Neuraminidase-specific Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

A Controlled Double-Blind Comparison of Reactogenicity, Immunogenicity, and Protective Efficacy of Whole-Virus and Split-Product Influenza Vaccines in Children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Preparation and characterization of a purified influenza virus neuraminidase vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Egg-adapted replication-restricted virus protects mice against lethal influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Neuraminidase Content of Influenza Vaccines and Neuraminidase Antibody Responses after Vaccination of Immunologically Primed and Unprimed Populations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Influenza: viral determinants of the pathogenicity and epidemicity of an invariant disease of variable occurrence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Protection of mice with recombinant influenza virus neuraminidase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Cross‐Reactive H1N1 Antibody Responses to a Live Attenuated Influenza Vaccine in Children: Implication for Selection of Vaccine Strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Complementation of recombinant baculoviruses by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.006

7 January 2021

Identifiers

10.1016/J.VIROL.2005.06.006

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45438480&oldid=2076954432"